Modeling the Potential Role of Inactivated Poliovirus Vaccine to Manage the Risks of Oral Poliovirus Vaccine Cessation
Open accessThe DOI matches its Crossref record; 37 of the 39 references it cites were found in a registry or an index.
Abstract
Background The Global Polio Eradication Initiative plans to stop all oral poliovirus vaccine (OPV) after wild poliovirus eradication, starting with serotype 2. Stakeholders continue to discuss the role of using inactivated poliovirus vaccine (IPV) to manage the risks of circulating vaccine-derived polioviruses (cVDPVs) during the end game. Methods We use a poliovirus transmission and OPV evolution model to explore the impact of various routine immunization policies involving IPV on population immunity dynamics and the probability and magnitude of cVDPV emergences following OPV cessation. Results Adding a single IPV dose to an OPV-only routine immunization schedule at or just before OPV cessation produces very limited impact on the probability of cVDPV emergences and the number of expected polio cases in settings in which we expect cVDPVs in the absence of IPV use. The highest-cost option of switching to a 3-dose IPV schedule only marginally decreases cVDPV risks. Discontinuing supplemental immunization activities while introducing IPV prior to OPV cessation leads to an increase in cVDPV risks. Conclusions Introducing a dose of IPV in countries currently using OPV only for routine immunization offers protection from paralysis to successfully vaccinated recipients, but it does little to protect high-risk populations from cVDPV risks.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Diekmann, O., Heesterbeek, J. A. P., & Metz, J. A. J. (1990) · Journal of Mathematical Biology · doi:10.1007/bf00178324 · Cited by 5,091
VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION
Kew, O. M., Sutter, R. W., de Gourville, E. M., Dowdle, W. R., & Pallansch, M. A. (2005) · Annual Review of Microbiology · doi:10.1146/annurev.micro.58.030603.123625 · Cited by 703
Kew, O., Morris-Glasgow, V., Landaverde, M., Burns, C., Shaw, J., Garib, Z., André, J., Blackman, E., Freeman, C. J., Jorba, J., et al. (2002) · Science · doi:10.1126/science.1068284 · Cited by 600
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review.
Patriarca, P. A., Wright, P. F., & John, T. J. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.5.926 · Cited by 453
Mucosal Immunity Induced by Enhanced-Potency Inactivated and Oral Polio Vaccines
Onorato, I. M., Modlin, J. F., McBean, A. M., Thoms, M. L., Losonsky, G. A., & Bernier, R. H. (1991) · Journal of Infectious Diseases · doi:10.1093/infdis/163.1.1 · Cited by 246
Hird, T. R., & Grassly, N. C. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002599 · Cited by 221
Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-93
Oostvogel, P. M., van der Avoort, H. G. A. M., Mulders, M. N., van Loon, A. M., Conyn-van Spaendonck, M. A. E., Rümke, H. C., van Steenis, G., & van Wijngaarden, J. K. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92091-5 · Cited by 220
Vaccine Policy Changes and Epidemiology of Poliomyelitis in the United States
Alexander, L. N. (2004) · JAMA · doi:10.1001/jama.292.14.1696 · Cited by 203
Risks of Paralytic Disease Due to Wild or Vaccine‐Derived Poliovirus After Eradication
Tebbens, R. J. D., Pallansch, M. A., Kew, O. M., Cáceres, V. M., Jafari, H., Cochi, S. L., Sutter, R. W., Aylward, R. B., & Thompson, K. M. (2006) · Risk Analysis · doi:10.1111/j.1539-6924.2006.00827.x · Cited by 174
Self-citationInsidious reintroduction of wild poliovirus into Israel, 2013
Anis, E., Kopel, E., Singer, S. R., Kaliner, E., Moerman, L., Moran-Gilad, J., Sofer, D., Manor, Y., Shulman, L. M., Mendelson, E., et al. (2013) · Eurosurveillance · doi:10.2807/1560-7917.es2013.18.38.20586 · Cited by 162
Research works printed but not linked: 1
- World Health Organization, 2005, Cessation of Routine Oral Polio Vaccine (OPV) use after Global Polio Eradication: framework for national policy makers in OPV-using countries
Cited by
Modeling the Dynamics of Oral Poliovirus Vaccine Cessation
Thompson, K. M., & Tebbens, R. J. D. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit845 · Cited by 84
“Given the plans for OPV2 cessation, we use model inputs for type 2 [14, 17], although the concepts of this analysis extend to the other 2 serotypes.”
BackgroundMethodInfluentialSelf-citationPolio endgame: the global switch from tOPV to bOPV
Garon, J. R., Seib, K. G., Orenstein, W. A., Gonzalez, A. R., Blanc, D. C., Zaffran, M., & Patel, M. M. (2016) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1140041 · Cited by 85
Polio endgame: the global introduction of inactivated polio vaccine
Patel, M. M., Zipursky, S., Orenstein, W., Garon, J. R., & Zaffran, M. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1001750 · Cited by 77
“However, if IPV protects against paralytic disease but has little impact against fecal-oral transmission, modeling suggests that IPV would not contribute toward interruption of transmission in the context of an outbreak in settings of high force of infection [43].”
BackgroundAn economic analysis of poliovirus risk management policy options for 2013–2052
Tebbens, R. J. D., Pallansch, M. A., Cochi, S. L., Wassilak, S. G. F., & Thompson, K. M. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1112-8 · Cited by 73
“We assume tOPV intensification leading up to OPV2 cessation maximizes population immunity at OPV2 cessation and avoids cVDPV2 emergences after OPV2 cessation [24, 52] and sufficient bOPV use before OPV13 cessation to avoid subsequent cVDPVs.”
BackgroundMethodInfluentialSelf-citationModeling Options to Manage Type 1 Wild Poliovirus Imported Into Israel in 2013
Kalkowska, D. A., Tebbens, R. J. D., Grotto, I., Shulman, L. M., Anis, E., Wassilak, S. G. F., Pallansch, M. A., & Thompson, K. M. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu674 · Cited by 65
“Further studies should continue to explore the dynamics of population immunity and OPV cessation [22, 23, 29, 30].”
Self-citationReview of poliovirus modeling performed from 2000 to 2019 to support global polio eradication
Thompson, K. M., & Kalkowska, D. A. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1791093 · Cited by 68
“In 2014, KRI modeled the dynamics of coordinated cessation of serotype 2 OPV (OPV2) without [38] and with [39] IPV, which”
BackgroundMethodResultInfluentialSelf-citationKalkowska, D. A., Tebbens, R. J. D., Pallansch, M. A., Cochi, S. L., Wassilak, S. G. F., & Thompson, K. M. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-0791-5 · Cited by 57
“Policy makers should recognize that choices made to achieve and maintain high levels of population immunity could impact the success or failure of polio eradication and the investment required in ongoing surveillance to ensure confidence about the absence of silent circulation when observed cases and/or signals from e…”
BackgroundSelf-citationPreventing Vaccine-Derived Poliovirus Emergence during the Polio Endgame
Pons-Salort, M., Burns, C. C., Lyons, H. M., Blake, I. M., Jafari, H. S., Oberste, M. S., Kew, O. M., & Grassly, N. C. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005728 · Cited by 60
“Therefore, the impact of IPV on VDPV2 emergence and transmission may be limited [39], leaving populations at risk of silent transmission of poliovirus.”
BackgroundTebbens, R. J. D., Hampton, L. M., & Thompson, K. M. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1537-8 · Cited by 50
“, defined as the collective level of protection to serotype 2 poliovirus transmission of all individuals in a population) as new birth cohorts accumulate with no exposure to serotype 2 live polioviruses [8, 9].”
BackgroundSelf-citationTebbens, R. J. D., Pallansch, M. A., & Thompson, K. M. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1115-5 · Cited by 47
“Modeling further suggests that population immunity to poliovirus transmission will drop significantly and fairly quickly after OPV cessation in most developing countries, regardless of IPV use due to both new birth cohorts that only receive IPV and waning immunity in those previously immunized or exposed to LPVs [13].”
BackgroundSelf-citationTebbens, R. J. D., Hampton, L. M., & Thompson, K. M. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1536-9 · Cited by 47
“Thus, failure to intensify tOPV use prior to the switch not only increases the risk of the creation of indigenous cVDPV2s, [3, 4, 7, 10, 22, 25] but also increases the risk of cVDPV2 outbreaks associated with a non-synchronous switch.”
BackgroundInfluentialSelf-citationWild and vaccine-derived poliovirus circulation, and implications for polio eradication
Lopalco, P. L. (2016) · Epidemiology and Infection · doi:10.1017/s0950268816002569 · Cited by 47
Thompson, K. M., & Tebbens, R. J. D. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix108 · Cited by 41
“The increased use of inactivated poliovirus vaccine (IPV), which results in a weaker immune response at the individual level and leads to relatively lower population immunity to transmission than OPV, will not play an important role in preventing cVDPVs in OPV-using countries prior to bOPV cessation [50] , substantial…”
BackgroundSelf-citationPolio Eradicators Use Integrated Analytical Models to Make Better Decisions
Thompson, K. M., Tebbens, R. J. D., Pallansch, M. A., Wassilak, S. G. F., & Cochi, S. L. (2015) · INFORMS Journal on Applied Analytics · doi:10.1287/inte.2014.0769 · Cited by 41
“More recently, we also provided critical information for the partners related to managing cVDPV risks in the transition from the interruption of WPV transmission to OPV cessation and beyond (e.g., Thompson and Duintjer Tebbens 2014, Duintjer Tebbens and Thompson 2014).”
BackgroundSelf-citationTebbens, R. J. D., Pallansch, M. A., Cochi, S. L., Ehrhardt, D. T., Farag, N. H., Hadler, S. C., Hampton, L. M., Martinez, M., Wassilak, S. G. F., & Thompson, K. M. (2018) · Risk Analysis · doi:10.1111/risa.12962 · Cited by 40
“15 Based on judgment and calibration within ranges used for other populations(10,20,26) to match incidence pattern R0 peak day (day of year) -Pakistan 180 (Jun.”
BackgroundMethodSelf-citationThompson, K. M., Kalkowska, D. A., & Tebbens, R. J. D. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.02.013 · Cited by 38
“We extend our prior modeling [4,15,17–20,22–24] to characterize vulnerability to re-established transmission and options that IPV-only using countries may consider to reduce or eliminate their vulnerability (see Appendix A).”
InfluentialSelf-citationAssessing the stability of polio eradication after the withdrawal of oral polio vaccine
Famulare, M., Selinger, C., McCarthy, K. A., Eckhoff, P. A., & Chabot‐Couture, G. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2002468 · Cited by 41
Tebbens, R. J. D., & Thompson, K. M. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1114-6 · Cited by 36
“circulating partially- or fully-reverted OPV-related viruses following OPV cessation [21–23].”
BackgroundResultInfluentialSelf-citationPoliovirus vaccination during the endgame: insights from integrated modeling
Tebbens, R. J. D., & Thompson, K. M. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1322514 · Cited by 36
“However, motivated by modeling results [21,42], the GPEI subsequently recognized the need to conduct more tOPV SIAs in 2015 and 2016 leading up to OPV2 cessation to minimize the probability of cVDPV2 outbreaks after OPV2 cessation [37].”
ResultSelf-citationReflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame
Thompson, K. M., & Kalkowska, D. A. (2020) · Risk Analysis · doi:10.1111/risa.13484 · Cited by 37
“…small role that IPV introduction shortly before OPV2 cessation might play with respect to mitigating the risks of cVDPV2s after OPV2 cessation, and recommended that the GPEI should not give countries a false sense of security from the introduction of IPV (Duintjer Tebbens & Thompson, 2014).”
BackgroundSelf-citationTebbens, R. J. D., Hampton, L. M., Wassilak, S. G. F., Pallansch, M. A., Cochi, S. L., & Thompson, K. M. (2016) · Journal of Vaccines & Vaccination · doi:10.4172/2157-7560.1000340 · Cited by 32
“Due to the limited intestinal immunity provided by the inactivated poliovirus vaccine (IPV) [10-13], the addition of IPV to routine immunization (RI) schedules does not provide much reduction in cVDPV risks in populations at highest risk of such outbreaks [14-16].”
BackgroundMethodInfluentialSelf-citationTebbens, R. J. D., & Thompson, K. M. (2016) · Epidemiology and Infection · doi:10.1017/s0950268816002302 · Cited by 29
Self-citationUsing integrated modeling to support the global eradication of vaccine‐preventable diseases
Tebbens, R. J. D., & Thompson, K. M. (2018) · System Dynamics Review · doi:10.1002/sdr.1589 · Cited by 30
“…2005b; Thompson et al. 2006a), the counter-intuitive need to intensify OPV use prior to its cessation as opposed to a gradual phase-out (Duintjer Tebbens and Thompson 2014; Kalkowska et al. 2014b; Kalkowska et al. 2014a; Thompson and Duintjer Tebbens 2014a), the need to synchronize OPV…”
BackgroundSelf-citationThompson, K. M., & Tebbens, R. J. D. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1116-4 · Cited by 27
“The planned addition of a single dose of inactivated poliovirus vaccine (IPV) given at the time of the third trivalent (tOPV) dose of routine immunization (RI) for countries currently using OPV-only for immunization [1] appears to offer only marginal benefits for areas most at risk of cVDPVs after OPV cessation [3].”
BackgroundSelf-citationThompson, K. M., & Kalkowska, D. A. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1635463 · Cited by 28
“Despite significant emphasis by the GPEI on the introduction of IPV into national immunization programs in all countries, IPV plays a relatively minor role in population immunity to transmission in countries characterized predominantly by fecal-oral transmission [27,28].”
BackgroundSelf-citationThompson, K. M., & Tebbens, R. J. D. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix128 · Cited by 24
“The situation in Pakistan clearly reflects behavior predicted by models in the event of a failure to intensify tOPV use prior to OPV2 cessation [10, 29, 30].”
BackgroundMethodSelf-citationDynamics affecting the risk of silent circulation when oral polio vaccination is stopped
Koopman, J. S., Henry, C. J., Park, J. H., Eisenberg, M. C., Ionides, E. L., & Eisenberg, J. N. S. (2017) · Epidemics · doi:10.1016/j.epidem.2017.02.013 · Cited by 28
“Thompson, K.M., Pallansch, M.A., Duintjer Tebbens, R.J., Wassilak, S.G., Kim, J.H., Cochi, S.L., 2013a. Preeradication vaccine policy options for poliovirus infection and disease control.”
InfluentialTebbens, R. J. D., & Thompson, K. M. (2018) · Risk Analysis · doi:10.1111/risa.13194 · Cited by 23
“…of WPV1 to (1) prevent WPV1 importations (if other endemic countries remain), (2) prevent indigenous cVDPV1 emergences while OPV continues through certification, and (3) allow safe OPV cessation without subsequent cVDPV1 outbreaks (Duintjer Tebbens et al., 2016; Thompson & Duintjer Tebbens, 2014).”
BackgroundSelf-citationTebbens, R. J. D., Pallansch, M. A., Wassilak, S. G. F., Cochi, S. L., & Thompson, K. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130123 · Cited by 25
“Consistent with prior work,[10, 33] the addition of a single IPV RI dose given with the third dose of OPV in RI from January 1, 2015 does not yield a large impact on population Quality and Frequency of Polio Vaccination Nigeria”
MethodResultSelf-citationThompson, K. M., & Tebbens, R. J. D. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1113-7 · Cited by 25
“Current timing plans that include the introduction of IPV with the third dose of OPV in RI do not promise to provide much protection from cVDPVs or VAPP [30].”
BackgroundInfluentialSelf-citationThe Potential Benefits of a new Poliovirus Vaccine for Long-Term Poliovirus Risk Management
Tebbens, R. J. D., & Thompson, K. M. (2016) · Future Microbiology · doi:10.2217/fmb-2016-0126 · Cited by 22
Self-citationOutbreak response strategies with type 2-containing oral poliovirus vaccines
Kalkowska, D. A., Wassilak, S. G. F., Pallansch, M. A., Burns, C. C., Wiesen, E., Durry, E., Badizadegan, K., & Thompson, K. M. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.060 · Cited by 22
Self-citationTebbens, R. J. D., & Thompson, K. M. (2017) · MDM Policy & Practice · doi:10.1177/2381468317697002 · Cited by 20
Self-citationStopping a polio outbreak in the midst of war: Lessons from Syria
Mbaeyi, C., Moran, T. J., Wadood, M. Z., Ather, F., Sykes, E., Nikulin, J., Safadi, M. A., Stehling-Ariza, T., Zomahoun, L., Ismaili, A., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.045 · Cited by 18
Thompson, K. M., Kalkowska, D. A., & Badizadegan, K. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1098419 · Cited by 19
Self-citationKalkowska, D. A., & Thompson, K. M. (2020) · Risk Analysis · doi:10.1111/risa.13471 · Cited by 19
“…introduction of IPV demonstrates that IPV has not accelerated WPV1 eradication, and multiple studies warn that IPV use in national immunization programs can mask live poliovirus transmission (Duintjer Tebbens & Thompson, 2014; Mangal, Aylward, & Grassly, 2013; Thompson & Duintjer Tebbens, 2012).”
BackgroundSelf-citationPolio eradication: what kind of world do we want?
Thompson, K. M. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00458-8 · Cited by 18
Self-citationTévi‐Bénissan, C., Okeibunor, J., du Châtellier, G. M., Assefa, A., Biey, J., Cheikh, D., Shibeshi, M. E., Anya, B.-P. M., Dao, H., Yusuf, N., et al. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw616 · Cited by 16
“However, it is well recognized that cVDPV2 outbreaks, caused either by circulating strains and/or newly emerged strains, could occur after the switch given that a high proportion of persons susceptible to infections with type 2 polioviruses will increase over time from new birth cohorts not receiving tOPV and because…”
BackgroundCoordinated global cessation of oral poliovirus vaccine use: Options and potential consequences
Kalkowska, D. A., Wassilak, S. G. F., Wiesen, E., Burns, C. C., Pallansch, M. A., Badizadegan, K., & Thompson, K. M. (2023) · Risk Analysis · doi:10.1111/risa.14158 · Cited by 15
“One analysis also explored the role of inactivated poliovirus vaccine (IPV) in RI and highlighted its expected inability to stop outbreaks, particularly in the places most likely to experience outbreaks (Duintjer Tebbens & Thompson, 2014).”
BackgroundSelf-citationWang, H. (2020) · China CDC Weekly · doi:10.46234/ccdcw2020.046 · Cited by 16
“MMWR Morb Mortal Wkly Rep 2019;68 (20):458 − 62.”
Tebbens, R. J. D., Hampton, L. M., & Thompson, K. M. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3074-0 · Cited by 12
“IPV use could play a small role in decreasing risks from unauthorized bOPV use, with the cumulative effect on population immunity to serotype 1 transmission from IPV administered through RI over years being greater than the immediate effect of IPV on serotype 2 transmission at the time of the tOPVbOPV switch [23, 30,…”
BackgroundSelf-citationThompson, K. M., & Badizadegan, K. (2024) · Pathogens · doi:10.3390/pathogens13060435 · Cited by 11
Self-citationLiu, Y., Wang, J., Liu, S., Du, J., Wang, L., Gu, W., Xu, Y., Zuo, S., Xu, E., & An, Z. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.01.034 · Cited by 9
Outbreak management strategies for cocirculation of multiple poliovirus types
Kalkowska, D. A., Badizadegan, K., & Thompson, K. M. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.04.037 · Cited by 10
Self-citationPolio endgame management: focusing on performance with or without inactivated poliovirus vaccine
Thompson, K. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60983-1 · Cited by 7
Self-citationBadizadegan, K., & Thompson, K. M. (2025) · PLOS Global Public Health · doi:10.1371/journal.pgph.0004168 · Cited by 5
“…time between expected AFP cases in populations with live poliovirus transmission by providing protection from paralysis, but not effectively stopping or preventing transmission, which implied potentially longer times required for confirmation of transmission of outbreak polioviruses [100,102–104].”
Self-citationBadizadegan, N. D., Wassilak, S. G. F., Estívariz, C. F., Wiesen, E., Burns, C. C., Bolu, O. O., & Thompson, K. M. (2024) · Pathogens · doi:10.3390/pathogens13090804 · Cited by 3
“…SIAs in children with prior live-poliovirus-induced immunity likely plays a minor role in stopping outbreak transmission because these children likely play a relatively less significant role in transmission than individuals in the population with no prior live-poliovirus-induced immunity [56,82].”
BackgroundSelf-citationSun, Y., Keskinocak, P., Peak, C. M., & Steimle, L. N. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128707
Metadata
- Authors
- Duintjer Tebbens, R. J., & Thompson, K. M.
- Affiliations
- University of Central Florida (US)
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-11
- Volume
- 210
- Issue
- suppl_1
- Pages
- S485-S497
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2054025229
- Cited by
- 48
- References
- 39
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 2 · 2020: 4 · 2019: 1 · 2018: 5 · 2017: 6 · 2016: 9 · 2015: 10 · 2014: 3
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Journal of International Crisis and Risk Communication Research (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Physical Sciences › Mathematics › Applied Mathematics › Mathematical and Theoretical Epidemiology and Ecology Models
- Keywords
- inactivated poliovirus vaccine, circulating vaccine-derived poliovirus, supplementary immunization activities, polio eradication
- MeSH terms
- Computer Simulation, Humans, Poliomyelitis, Poliovirus Vaccine, Inactivated, Poliovirus Vaccine, Oral, Vaccination, Disease Eradication
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.